{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:17:44Z","timestamp":1778905064128,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019734","name":"Kenya Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-017985"],"award-info":[{"award-number":["INV-017985"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-019400"],"award-info":[{"award-number":["INV-019400"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019778","name":"President's Malaria Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eclinm.2025.103735","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:53:17Z","timestamp":1767423197000},"page":"103735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Artemether-lumefantrine versus pyronaridine-artesunate for the treatment of malaria in patients with mild to moderate COVID-19 in Kenya and Burkina Faso: a randomised open-label trial (MALCOV)"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6138-6806","authenticated-orcid":false,"given":"Brian","family":"Tangara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hellen C.","family":"Barsosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tegwen","family":"Marlais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Moise T.","family":"Kabore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred B.","family":"Tiono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kephas","family":"Otieno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Wanjiku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morine","family":"Achieng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Onyango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Everlyne D.","family":"Ondieki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Aura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Telesphorus","family":"Odawo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin KA.","family":"Tetteh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issiaka","family":"Soulama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alphonse","family":"Ouedraogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel S.","family":"Serme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben I.","family":"Soulama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aissata","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie S.","family":"Badoum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Matthewman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Brazal-Monz\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Canizales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Drabko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Kariuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Lesosky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sodiomon B.","family":"Sirima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Drakeley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiko O.","family":"ter Kuile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103735_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103735_bib2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103735_bib3","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/14656566.2021.1898589","article-title":"Does hydroxychloroquine still have any role in the COVID-19 pandemic?","volume":"22","author":"Schilling","year":"2021","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.eclinm.2025.103735_bib4","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1111\/bph.15102","article-title":"Lung tissue distribution of drugs as a key factor for COVID-19 treatment","volume":"177","author":"Wang","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.eclinm.2025.103735_bib5","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/s41467-021-22446-z","article-title":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials","volume":"12","author":"Axfors","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2025.103735_bib6","article-title":"Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eclinm.2025.103735_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103723","article-title":"Learning from COVID-19: how drug hunters can prepare for the next pandemic","volume":"28","author":"Puhl","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.eclinm.2025.103735_bib8","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1021\/acsomega.0c05996","article-title":"Repurposing the Ebola and Marburg virus inhibitors tilorone, quinacrine, and pyronaridine: in vitro activity against SARS-CoV-2 and potential mechanisms","volume":"6","author":"Puhl","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.eclinm.2025.103735_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101873","article-title":"Antimalarial drugs inhibit the replication of SARS-CoV-2: an in vitro evaluation","volume":"37","author":"Gendrot","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.eclinm.2025.103735_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pt.2020.10.003","article-title":"Repurposing antimalarials to tackle the COVID-19 pandemic","volume":"37","author":"Krishna","year":"2021","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.eclinm.2025.103735_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01587-23","article-title":"Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses","volume":"14","author":"Ardanuy","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.eclinm.2025.103735_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine","volume":"37","author":"White","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eclinm.2025.103735_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.649532","article-title":"Repurposing anti-malaria phytomedicine artemisinin as a COVID-19 drug","volume":"12","author":"Uckun","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eclinm.2025.103735_bib14","article-title":"In vitro efficacy of artemisinin-based treatments against SARS-CoV-2","volume":"11","author":"Zhou","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2025.103735_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/bmb\/ldac037","article-title":"Drug repurposing for COVID-19: current evidence from randomized controlled adaptive platform trials and living systematic reviews","volume":"147","author":"Augustin","year":"2023","journal-title":"Br Med Bull"},{"key":"10.1016\/j.eclinm.2025.103735_bib16","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/pharmaceutics15030838","article-title":"Application of minimal physiologically-based pharmacokinetic model to simulate lung and Trachea exposure of pyronaridine and artesunate in hamsters","volume":"15","author":"Kang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.eclinm.2025.103735_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13865","article-title":"PBPK-led assessment of antimalarial drugs as candidates for Covid-19: simulating concentrations at the site of action to inform repurposing strategies","volume":"17","author":"Abla","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.eclinm.2025.103735_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194180","article-title":"Performance of the inFLUenza patient-reported outcome (FLU-PRO) diary in patients with influenza-like illness (ILI)","volume":"13","author":"Powers","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2025.103735_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab517","article-title":"Performance of the inFLUenza patient-reported outcome plus (FLU-PRO plus) instrument in patients with coronavirus disease 2019","volume":"8","author":"Richard","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.eclinm.2025.103735_bib20","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3201\/eid2608.201246","article-title":"US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome coronavirus 2","volume":"26","author":"Lu","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.eclinm.2025.103735_bib21","series-title":"Lancet Global Health","article-title":"Uncomplicated malaria as a risk factor for COVID-19 in Western Kenya and Burkina Faso (MALCOV): a prospective cohort study","author":"Barsosio","year":"2025"},{"key":"10.1016\/j.eclinm.2025.103735_bib22","first-page":"1192","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"10.1016\/j.eclinm.2025.103735_bib23","article-title":"Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza","author":"Bae","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.eclinm.2025.103735_bib24","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/591195","article-title":"The antiviral activities of artemisinin and artesunate","volume":"47","author":"Efferth","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2025.103735_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007890","article-title":"Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection","volume":"13","author":"Lane","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.eclinm.2025.103735_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acsinfecdis.2c00091","article-title":"Pyronaridine protects against SARS-CoV-2 infection in mouse","volume":"8","author":"Puhl","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.eclinm.2025.103735_bib27","series-title":"Shin Poong Pharma unveils P2 results of Covid-19 treatment. In: KoreoBioMed","author":"Han-soo","year":"2021"},{"key":"10.1016\/j.eclinm.2025.103735_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104322","article-title":"Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: a randomised, open-label, multi-arm, phase 2 clinical trial","volume":"86","author":"Chandiwana","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.eclinm.2025.103735_bib29","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s13577-021-00489-0","article-title":"ACE2 mutation might explain lower COVID-19 burden in malaria endemic areas","volume":"34","author":"De","year":"2021","journal-title":"Hum Cell"},{"key":"10.1016\/j.eclinm.2025.103735_bib30","series-title":"Poster: 6165: impact of Plasmodium falciparum malaria on SARS-CoV-2 antibody responses in Kenya and Burkina Faso (MALCOV)","author":"Marlais","year":"2023"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:04:35Z","timestamp":1778904275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025006704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"alternative-id":["S2589537025006704"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103735","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artemether-lumefantrine versus pyronaridine-artesunate for the treatment of malaria in patients with mild to moderate COVID-19 in Kenya and Burkina Faso: a randomised open-label trial (MALCOV)","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103735"}}